I agree that this site is using cookies. You can find further informations here.
X
Furqan, Fateeha
28  results:
Search for persons X
?
1

Phase 1 Trial of LV20.19 CAR T-Cells for Relapsed, Refracto..:

Shah, Nirav N. ; Atallah, Ehab L. ; Abedin, Sameem...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S35-S36 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Fresh Versus Cryopreserved LV20.19 CAR T-Cell Therapy for R..:

Furqan, Fateeha ; Szabo, Aniko ; Kearl, Tyce...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S211-S212 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Outpatient Administration of Commercial antiCD19 and Antibc..:

Furqan, Fateeha ; Bhatlapenumarthi, Vineel ; Farrukh, Faiqa...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S211 , 2024
Link: https://doi.org/10.1016/..
 
?
4

Outpatient Administration of CAR T-cell Therapies Using a S..:

Furqan, Fateeha ; Bhatlapenumarthi, Vineel ; Dhakal, Binod...
Blood Advances.  , 2024
Link: https://doi.org/10.1182/..
 
?
5

Timing of Toxicities and Non-Relapse Mortality Following CA..:

Wesson, William ; Dima, Danai ; Suleman, Nahid...
Transplantation and Cellular Therapy.  , 2024
Link: https://doi.org/10.1016/..
 
?
6

A Multicenter Experience: Duration of Mandatory CRS and Ica..:

Wesson, William ; Dima, Danai ; Davis, James...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S207-S208 , 2024
Link: https://doi.org/10.1016/..
 
?
7

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidenc..:

Bowers, Jackson T. ; Anna, Jacob ; Bair, Steven M....
Blood Advances.  7 (2023)  21 - p. 6630-6638 , 2023
Link: https://doi.org/10.1182/..
 
?
8

Clinical Characteristics and Patient Outcomes with HLH-like..:

Furqan, Fateeha ; Aschenbrenner, Emillie ; Talano, Julie...
Transplantation and Cellular Therapy.  29 (2023)  2 - p. S131-S132 , 2023
Link: https://doi.org/10.1016/..
 
?
9

Multispecific CAR T Cells Deprive Lymphomas of Escape via A..:

Furqan, Fateeha ; Shah, Nirav N.
Annual Review of Medicine.  74 (2023)  1 - p. 279-291 , 2023
Link: https://doi.org/10.1146/..
 
?
10

Favorable Outcomes of Acute Leukemia in Cord Blood Transpla..:

Neupane, Niraj ; Al-Kaabneh, Basil ; Tbakhi, Bushra...
Transplantation and Cellular Therapy.  29 (2023)  2 - p. S285 , 2023
Link: https://doi.org/10.1016/..
 
?
11

Results from a Phase 1/2 Study of Tandem, Bispecific Anti-C..:

Shah, Nirav N. ; Furqan, Fateeha ; Szabo, Aniko...
Transplantation and Cellular Therapy.  29 (2023)  2 - p. S33-S34 , 2023
Link: https://doi.org/10.1016/..
 
?
12

Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Ri..:

Furqan, Fateeha ; Johnson, Bryon D ; Hamadani, Mehdi..
Transplantation and Cellular Therapy.  29 (2023)  2 - p. S377-S378 , 2023
Link: https://doi.org/10.1016/..
 
?
13

Salvage polatuzumab and allogeneic transplant rescue patien..:

Furqan, Fateeha ; Maring, Morgan ; Szabo, Aniko...
Blood Advances.  7 (2023)  11 - p. 2463-2467 , 2023
Link: https://doi.org/10.1182/..
 
?
14

Impact of thiotepa dose-intensity in primary diffuse large ..:

Arshad, Shanze ; Fang, Xi ; Ahn, Kwang W....
Bone Marrow Transplantation.  58 (2023)  11 - p. 1203-1208 , 2023
Link: https://doi.org/10.1038/..
 
?
15

Loncastuximab tesirine in relapsed or refractory diffuse la..:

Furqan, Fateeha ; Hamadani, Mehdi
Therapeutic Advances in Hematology.  13 (2022)  - p. 204062072210875 , 2022
Link: https://doi.org/10.1177/..
 
1-15